C WorldWide Group’s Iovance Biotherapeutics IOVA Stock Holding History

C WorldWide Group’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.24M	Hold	1,260,000	–	–	0.13%	66
2026 Q1	$4.42M	Hold	1,260,000	–	–	0.09%	73
2025 Q4	$3.44M	Hold	1,260,000	–	–	0.06%	76
2025 Q3	$2.73M	Hold	1,260,000	–	–	0.04%	81
2025 Q2	$2.17M	Hold	1,260,000	–	–	0.03%	81
2025 Q1	$4.2M	Hold	1,260,000	–	–	0.05%	69
2024 Q4	$9.32M	Hold	1,260,000	–	–	0.11%	65
2024 Q3	$11.8M	Hold	1,260,000	–	–	0.12%	64
2024 Q2	$10.1M	Buy	1,260,000 +200,000	+19%	+$2.14M	0.11%	65
2024 Q1	$15.7M	Sell	1,060,000 -300,000	-22%	-$3.49M	0.18%	57
2023 Q4	$11.1M	Hold	1,360,000	–	–	0.15%	57
2023 Q3	$6.19M	Hold	1,360,000	–	–	0.08%	64
2023 Q2	$9.57M	Hold	1,360,000	–	–	0.12%	59
2023 Q1	$8.31M	Hold	1,360,000	–	–	0.11%	62
2022 Q4	$8.69M	Buy	1,360,000 +200,000	+17%	+$1.56M	0.12%	45
2022 Q3	$11.1M	Hold	1,160,000	–	–	0.15%	41
2022 Q2	$12.8M	Buy	+1,160,000	New	+$15.2M	0.16%	39
2019 Q2	–	Sell	-226,681	Closed	-$2.16M	–	98
2019 Q1	$2.16M	Hold	226,681	–	–	0.03%	93
2018 Q4	$2.01M	Sell	226,681 -173,922	-43%	-$1.68M	0.03%	78
2018 Q3	$4.51M	Buy	400,603 +15,157	+4%	+$215K	0.06%	70
2018 Q2	$4.93M	Buy	+385,446	New	+$5.63M	0.07%	66

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

C WorldWide Group's IOVA Position: Q2 2026 in Review

C WorldWide Group held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 1,260,000 shares worth $5.24M. The position accounts for 0.13% of the portfolio, ranked #66.

C WorldWide Group first reported a position in IOVA in Q2 2018 and has held it in 21 quarters since. The position peaked at $15.7M in Q1 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

C WorldWide Group held 1,260,000 shares of Iovance Biotherapeutics worth $5.24M as of Q2 2026.
C WorldWide Group left its Iovance Biotherapeutics share count unchanged in Q2 2026.
Iovance Biotherapeutics made up 0.13% of C WorldWide Group's portfolio in Q2 2026, its #66 holding.
C WorldWide Group first reported a position in Iovance Biotherapeutics in Q2 2018 and has held it in 21 quarters since.
C WorldWide Group's Iovance Biotherapeutics position peaked at $15.7M in Q1 2024.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on C WorldWide Group's 13F filing for Q2 2026, filed 4 Aug 2026.